Cited by 328Cannabis and Cannabinoid ResearchReceptor Mechanisms and SignalingNeuropeptides and Animal Physiology

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis

Open access

Rios, Carl, Gomes, Ivone, Devi, Lakshmi A·2006·British Journal of Pharmacology

DOI 10.1038/sj.bjp.0706757PMC PMC1751792

Open this paper in CoChat — free account Open PDF

Abstract

Several studies have described functional interactions between opioid and cannabinoid receptors; the underlying mechanism(s) have not been well explored. One possible mechanism is direct receptor–receptor interactions, as has been demonstrated for a number of G‐protein‐coupled receptors. In order to investigate interactions between opioid and cannabinoid receptors, we epitope tagged μ, δ and κ opioid receptors with Renilla luciferase and CB1 cannabinoid or CCR5 chemokine receptors with yellow fluorescent protein and examined the extent of substrate hydrolysis induced bioluminescence resonance energy transfer (BRET) signal. We find that coexpression of opioid receptors with cannabinoid receptors, but not with chemokine receptors, leads to a significant increase in the level of BRET signal, suggesting that the opioid–cannabinoid interactions are receptor specific. In order to examine the implications of these interactions to signaling, we used GTP γ S binding and mitogen‐activated protein kinase (MAPK) phosphorylation assays and examined the effect of receptor activation on signaling. We find that the μ receptor‐mediated signaling is attenuated by the CB1 receptor agonist; this effect is reciprocal and is seen in heterologous cells and endogenous tissue expressing both receptors. In order to explore the physiological consequences of this interaction, we examined the effect of receptor activation on the extent of Src and STAT3 phosphorylation and neuritogenesis in Neuro‐2A cells. We find that the simultaneous activation of μ opioid and CB1 cannabinoid receptors leads to a significant attenuation of the response seen upon activation of individual receptors, implicating a role for receptor–receptor interactions in modulating neuritogenesis. British Journal of Pharmacology (2006) 148, 387–395. doi:10.1038/sj.bjp.0706757

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0706757

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,618
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor
KUNISHIMA, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., & Morikawa, K. (2000) · Nature · doi:10.1038/35039564 · Cited by 1,249
Heterodimerization is required for the formation of a functional GABAB receptor
White, J. H. M., Wise, A., Main, M. J., Green, A., Fraser, N. J., Disney, G. H., Barnes, A. A., Emson, P. C., Foord, S. M., & Marshall, F. H. (1998) · Nature · doi:10.1038/25354 · Cited by 1,165
International Union of Pharmacology. XII. Classification of opioid receptors
Bn, D., Cesselin, F., Raghubir, R., Reisine, T., Bradley, P. B., Portoghese, P. S., & Hamon, M. (1996) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06958-3 · Cited by 732
Dimerization: An Emerging Concept for G Protein–Coupled Receptor Ontogeny and Function
Angers, S., Salahpour, A., & Bouvier, M. (2002) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091701.082314 · Cited by 586
Pharmacological and biochemical interactions between opioids and cannabinoids
Manzanares, J., Corchero, J., Romero, J., Fernández‐Ruíz, J., Ramos, J. A., & Fuentes, J. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01339-5 · Cited by 391
A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia
Gomes, I., Gupta, A., Filipovska, J., Szeto, H. H., Pintar, J. E., & Devi, L. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307601101 · Cited by 386
Self-citation
Ultrastructural Localization of the CB1 Cannabinoid Receptor in μ-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus
Rodriguez, J. J., Mackie, K., & Pickel, V. M. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00823.2001 · Cited by 372
Oligomerization of opioid receptors with beta 2-adrenergic receptors: A role in trafficking and mitogen-activated protein kinase activation
Jordan, B. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011384898 · Cited by 328

Flagged first, then by citations

Show all 42 references

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Marzo, V. D., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,666
Molecular mechanisms of opioid receptor-dependent signaling and behavior
Al-Hasani, R., & Bruchas, M. R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318238bba6 · Cited by 1,067
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
The emerging functions of endocannabinoid signaling during CNS development
Harkany, T., Guzmán, M., Galve‐Roperh, I., Berghuis, P., Devi, L. A., & Mackie, K. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.004 · Cited by 449
Self-citation
The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
G protein-coupled receptor heteromers
Gomes, I., Ayoub, M. A., Fujita, W., Jaeger, W. C., Pfleger, K. D. G., & Devi, L. A. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135952 · Cited by 262
Self-citation
Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes
Smith, N. J., & Milligan, G. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002667 · Cited by 261
Diversity of molecular targets and signaling pathways for CBD
de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 284
Self-citation
Genetic Dissection of Behavioural and Autonomic Effects of Δ9-Tetrahydrocannabinol in Mice
Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G., Wotjak, C. T., Lutz, B., & Marsicano, G. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050269 · Cited by 261
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal
Scavone, J. L., Sterling, R. C., & Van Bockstaele, E. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.034 · Cited by 209
CB2receptor‐mediated migration of immune cells: it can go either way
Miller, A. M., & Stella, N. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707523 · Cited by 215
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives
Sobczak, M., Sałaga, M., Storr, M., & Fichna, J. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0753-x · Cited by 203
Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities
Bosier, B., Muccioli, G. G., Hermans, E., & Lambert, D. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.02.013 · Cited by 193
Endocannabinoid functions controlling neuronal specification during brain development
Harkany, T., Keimpema, E., Barabás, K., & Mulder, J. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.011 · Cited by 194
G protein-coupled receptor dimerisation: Molecular basis and relevance to function
Milligan, G. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.021 · Cited by 174
Cannabinoid–opioid interactions during neuropathic pain and analgesia
Bushlin, I., Rozenfeld, R., & Devi, L. A. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.09.009 · Cited by 163
Self-citation
Regulation of CB 1 cannabinoid receptor trafficking by the adaptor protein AP‐3
Rozenfeld, R., & Devi, L. A. (2008) · The FASEB Journal · doi:10.1096/fj.07-102731 · Cited by 160
Self-citation
μ-Opioid Receptor Forms a Functional Heterodimer With Cannabinoid CB1 Receptor: Electrophysiological and FRET Assay Analysis
Hojo, M., Sudo, Y., Ando, Y., Minami, K., Takada, M., Matsubara, T., Kanaide, M., Taniyama, K., Sumikawa, K., & Uezono, Y. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08244fp · Cited by 148
Exploring a role for heteromerization in GPCR signalling specificity
Rozenfeld, R., & Devi, L. A. (2010) · Biochemical Journal · doi:10.1042/bj20100458 · Cited by 144
Self-citation
Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases
Haspula, D., & Clark, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207693 · Cited by 147
Physiology of the orexinergic/hypocretinergic system: a revisit in 2012
Kukkonen, J. P. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00227.2012 · Cited by 138
The complications of promiscuity: endocannabinoid action and metabolism
Alexander, S. P. H., & Kendall, D. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707456 · Cited by 136
Cannabis and the developing brain: Insights from behavior
Trezza, V., Cuomo, V., & Vanderschuren, L. J. M. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.058 · Cited by 131
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 132
The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?
Moreno, E., Cavic, M. R., Krivokuća, A., Casadó, V., & Canela, E. I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00339 · Cited by 126
Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors
Pryce, G., & Baker, D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707003 · Cited by 129
Advances in the field of cannabinoid–opioid cross‐talk
Robledo, P., Berrendero, F., Ozaita, A., & Maldonado, R. J. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00107.x · Cited by 121
Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling
Moreno, E., Andradas, C., Medrano, M., Caffarel, M. M., Pérez-Gómez, E., Blasco-Benito, S., Gómez‐Cañas, M., Pazos, M. R., Irving, A. J., Lluı́s, C., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.561761 · Cited by 120
Molecular Pharmacology of δ-Opioid Receptors
Gendron, L., Cahill, C. M., von Zastrow, M., Schiller, P. W., & Piñeyro, G. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.008979 · Cited by 133
Wiring and firing neuronal networks: endocannabinoids take center stage
Harkany, T., Mackie, K., & Doherty, P. (2008) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2008.08.007 · Cited by 125
Cannabinoid CB1receptor‐interacting proteins: novel targets for central nervous system drug discovery?
Smith, T. H., Sim‐Selley, L. J., & Selley, D. E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00777.x · Cited by 119
Hedonic Hotspots: Generating Sensory Pleasure in the Brain
Smith, K. S., Mahler, S. V., Peciña, S., & Berridge, K. C. (2009) · Oxford University Press eBooks · doi:10.1093/oso/9780195331028.003.0003 · Cited by 123
Class A G-Protein-Coupled Receptor (GPCR) Dimers and Bivalent Ligands
Hiller, C., Kühhorn, J., & Gmeiner, P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4004335 · Cited by 116
A day in the life of a G protein‐coupled receptor: the contribution to function of G protein‐coupled receptor dimerization
Milligan, G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707490 · Cited by 114
Ligand- and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor
Hudson, B. D., Hébert, T. E., & Kelly, M. E. M. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060251 · Cited by 110
Neurochemical basis of cannabis addiction
Maldonado, R. J., Berrendero, F., Ozaita, A., & Robledo, P. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.035 · Cited by 113
Cannabinoids and the Brain
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110
Role of receptor internalization in the agonist‐induced desensitization of cannabinoid type 1 receptors
Wu, D., Yang, L., Goschke, A., Stumm, R. K., Brandenburg, L., Liang, Y.-J., Höllt, V., & Koch, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05063.x · Cited by 107
ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids
Shah, S., Schwenk, E. S., Sondekoppam, R. V., Clarke, H. A., Zakowski, M. I., Lynn, R. R., Yeung, B., Nicholson, K., Schwartz, G. S., Hooten, W. M., et al. (2023) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2022-104013 · Cited by 113
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies
Seely, K. A., Brents, L. K., Franks, L. N., Rajasekaran, M., Zimmerman, S. M., Fantegrossi, W. E., & Prather, P. L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.046 · Cited by 103
Consequences of Perinatal Cannabis Exposure
Scheyer, A. F., Melis, M., Trezza, V., & Manzoni, O. J. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.08.010 · Cited by 106
Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A
Ward, R. J., Pediani, J. D., & Milligan, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.287649 · Cited by 99
The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor Oligomerization
Milligan, G. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.084780 · Cited by 98
Cannabinoids as anticancer therapeutic agents
Kovalchuk, O., & Kovalchuk, I. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1742952 · Cited by 97
Signal Transduction via Cannabinoid Receptors
Dalton, G. D., Bass, C. E., Horn, C. V., & Howlett, A. C. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824615 · Cited by 94
Molecular model of cannabis sensitivity in developing neuronal circuits
Keimpema, E., Mackie, K., & Harkany, T. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.004 · Cited by 95
Opioid Receptors and Signaling on Cells from the Immune System
Bidlack, J. M., Khimich, M., Parkhill, A. L., Sumagin, S., Sun, B., & Tipton, C. M. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9026-2 · Cited by 93
Characterization of cannabinoid-1 receptors in the locus coeruleus: Relationship with mu-opioid receptors
Scavone, J. L., Mackie, K., & Bockstaele, E. J. V. (2009) · Brain Research · doi:10.1016/j.brainres.2009.11.023 · Cited by 92
Endogenous opiates and behavior: 2006
Bodnar, R. J. (2007) · Peptides · doi:10.1016/j.peptides.2007.09.002 · Cited by 91
Modulatory effects of cannabinoids on brain neurotransmission
Cohen, K., Weizman, A., & Weinstein, A. M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14407 · Cited by 98
Interaction of the cannabinoid and opioid systems in the modulation of nociception
Welch, S. P. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782794 · Cited by 92
Dimerization with Cannabinoid Receptors Allosterically Modulates Delta Opioid Receptor Activity during Neuropathic Pain
Bushlin, I., Gupta, A., Stockton, S. D., Miller, L. K., & Devi, L. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049789 · Cited by 95
Self-citation
Looking for the role of cannabinoid receptor heteromers in striatal function
Ferré, S., Goldberg, S. R., Lluı́s, C., & Franco, R. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.076 · Cited by 89
G protein-coupled receptor dimers: Functional consequences, disease states and drug targets
Dalrymple, M. B., Pfleger, K. D. G., & Eidne, K. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.03.004 · Cited by 89
GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding
Gomes, I., Aryal, D. K., Wardman, J. H., Gupta, A., Gagnidze, K., Rodriguiz, R. M., Kumar, S., Wetsel, W. C., Pintar, J. E., Fricker, L. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312938110 · Cited by 89
Self-citation
G Protein-Coupled Receptor Heteromerization: A Role in Allosteric Modulation of Ligand Binding
Gomes, I., IJzerman, A. P., Ye, K., Maillet, É. L., & Devi, L. A. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070847 · Cited by 88
Self-citation
Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR R eview 10
Fujita, W., Gomes, I., & Devi, L. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12798 · Cited by 87
Self-citation
Receptor Heteromerization Expands the Repertoire of Cannabinoid Signaling in Rodent Neurons
Rozenfeld, R., Bushlin, I., Gomes, I., Tzavaras, N., Gupta, A., Neves, S. R., Battini, L., Gusella, G. L., Lachmann, A., Ma’ayan, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029239 · Cited by 87
Self-citation
Heterodimerization of human apelin and kappa opioid receptors: Roles in signal transduction
Li, Y., Chen, J., Bai, B., Du, H., YouWang, L., & Liu, H. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.12.012 · Cited by 86
Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors
Canals, M., & Milligan, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710300200 · Cited by 86
Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance
Naour, M. L., Akgün, E., Yekkirala, A. S., Lunzer, M. M., Powers, M. D., Kalyuzhny, A. E., & Portoghese, P. S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005219 · Cited by 85
Physical and functional interaction between CB1cannabinoid receptors and β2‐adrenoceptors
Hudson, B. D., Hébert, T. E., & Kelly, M. E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00681.x · Cited by 83
The μ‐opioid receptor agonist morphine, but not agonists at δ‐ or κ‐opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors
Da Fonseca Pacheco, D., Klein, A., De Castro Perez, A., Da Fonseca Pacheco, C. M., De Francischi, J. N., & Duarte, I. D. G. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.175 · Cited by 81
The endocannabinoid hydrolysis inhibitor SA-57: intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice
Wilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78
Opioid receptor heteromers in analgesia
Costantino, C. M., Gomes, I., Stockton, S. D., Lim, M. P., & Devi, L. A. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.5 · Cited by 81
Self-citation
Refining Efficacy: Allosterism and Bias in G Protein-Coupled Receptor Signaling
Luttrell, L. M., & Kenakin, T. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-160-4_1 · Cited by 81
Antinociceptive Action of Isolated Mitragynine from Mitragyna Speciosa through Activation of Opioid Receptor System
Shamima, A. R., Fakurazi, S., Hidayat, M. T., Hairuszah, I., Moklas, M. A. M., & Arulselvan, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911427 · Cited by 78
G protein-coupled receptor heteromers are key players in substance use disorder
Derouiche, L., & Massotte, D. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.026 · Cited by 76
Interacting Cannabinoid and Opioid Receptors in the Nucleus Accumbens Core Control Adolescent Social Play
Manduca, A., Lassalle, O., Sepers, M., Campolongo, P., Cuomo, V., Marsicano, G., Kieffer, B., Vanderschuren, L. J. M. J., Trezza, V., & Manzoni, O. J. J. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00211 · Cited by 73
Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.
Haney, M., Ramesh, D., Glass, A., Pavlicova, M., Bedi, G., & Cooper, Z. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.108 · Cited by 73
Methods used to study the oligomeric structure of G-protein-coupled receptors
Guo, H., An, S., Ward, R. J., Yang, Y., Liu, Y., Guo, X., Hao, Q., & Xu, T. (2017) · Bioscience Reports · doi:10.1042/bsr20160547 · Cited by 74
G‐protein‐coupled receptor heteromers: function and ligand pharmacology
Franco, R., Casadó, V., Cortés, A., Mallol, J., Ciruela, F., Ferré, S., Lluı́s, C., & Canela, E. I. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707571 · Cited by 71
Opioid switching and rotation in primary care: implementation and clinical utility
Slatkin, N. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903120158 · Cited by 70
Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans
Lofwall, M. R., Babalonis, S. L., Nuzzo, P. A., Elayi, C. S., & WALSH, S. L. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.05.002 · Cited by 70
Mu Opioid Receptor Heterodimers Emerge as Novel Therapeutic Targets: Recent Progress and Future Perspective
Zhang, L., Zhang, J., Hang, L., & Liu, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01078 · Cited by 69
Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: Opioid receptor dependency and molecular correlates
Butler, R. K., Rea, K., Lang, Y., Gavin, A. M., & Finn, D. P. (2008) · Pain · doi:10.1016/j.pain.2008.10.002 · Cited by 69
Central antinociception induced by µ‐opioid receptor agonist morphine, but not δ‐ or κ‐, is mediated by cannabinoid CB1receptor
Pacheco, D. D. F., Klein, A., Perez, A. C., Pacheco, C. M. D. F., Francischi, J. N., Reis, G. M. L., & Duarte, I. D. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00310.x · Cited by 68
The Cannabinoid Delta-9-tetrahydrocannabinol Mediates Inhibition of Macrophage Chemotaxis to RANTES/CCL5: Linkage to the CB2 Receptor
Raborn, E. S., Marciano‐Cabral, F., Buckley, N. E., Martin, B. R., & Cabral, G. A. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9077-z · Cited by 69
β2-Adrenergic Receptor Signaling in the Cardiac Myocyte is Modulated by Interactions With CXCR4
LaRocca, T. J., Schwarzkopf, M., Altman, P. R., Zhang, S., Gupta, A., Gomes, I., Alvin, Z. V., Champion, H. C., Haddad, G. E., Hajjar, R. J., et al. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181f713fe · Cited by 67
Self-citation
Basic neuroanatomy and neuropharmacology of cannabinoids
Breivogel, C. S., & Sim‐Selley, L. J. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782760 · Cited by 71
Triplet Puzzle: Homologies of Receptor Heteromers
Tarakanov, A. O., & Fuxé, K. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9313-5 · Cited by 65
Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of μ‐ and δ‐opioid receptor antagonists
Abul‐Husn, N. S., Sutak, M., Milne, B., & Jhamandas, K. H. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707277 · Cited by 65
Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions
Tadijan, A., Vlašić, I., Vlainić, J., Đikić, D., Oršolić, N., & Jembrek, M. J. (2022) · Antioxidants · doi:10.3390/antiox11102049 · Cited by 68
Induced Association of μ Opioid (MOP) and Type 2 Cholecystokinin (CCK2) Receptors by Novel Bivalent Ligands
Zheng, Y., Akgün, E., Harikumar, K. G., Hopson, J. A., Powers, M. D., Lunzer, M. M., Miller, L. J., & Portoghese, P. S. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800174p · Cited by 60
Impact of Efficacy at the μ-Opioid Receptor on Antinociceptive Effects of Combinations of μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists
Maguire, D. R., & France, C. P. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216648 · Cited by 59
Agonist-dependent μ-opioid receptor signaling can lead to heterologous desensitization
Chu, J., Zheng, H., Zhang, Y., Loh, H. H., & Law, P. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.12.003 · Cited by 58
Interactions between Δ9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociception
Li, J., McMahon, L. R., Gerak, L. R., Becker, G. L., & France, C. P. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1157-0 · Cited by 57
Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells
Ciaglia, E., Torelli, G., Pisanti, S., Picardi, P., D’Alessandro, A., Laezza, C., Malfitano, A. M., Fiore, D., Zottola, A. C. P., Proto, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3895 · Cited by 56
Psychopharmacology of the endocannabinoids: far beyond anandamide
Pamplona, F. A., & Takahashi, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111405357 · Cited by 61
Salvinorin A Reduces Mechanical Allodynia and Spinal Neuronal Hyperexcitability Induced by Peripheral Formalin Injection
Guida, F., Luongo, L., Aviello, G., Palazzo, E., Chiaro, M. D., Gatta, L., Boccella, S., Marabese, I., Zjawiony, J. K., Capasso, R., et al. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-60 · Cited by 56
Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain
Zielińska, A., Sałaga, M., Włodarczyk, M., & Fichna, J. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3218-0 · Cited by 56
Morphine Modulation of Thrombospondin Levels in Astrocytes and Its Implications for Neurite Outgrowth and Synapse Formation
Ikeda, H., Miyatake, M., Koshikawa, N., Ochiai, K., Yamada, K., Kiss, A., Donlin, M. J., Panneton, W. M., Churchill, J. D., Green, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.109827 · Cited by 54
Heterodimerization of apelin receptor and neurotensin receptor 1 induces phosphorylation of ERK1/2 and cell proliferation via Gαq‐mediated mechanism
Bai, B., Cai, X., Jiang, Y., Karteris, E., & Chen, J. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12404 · Cited by 53
Physical Association between Neuropeptide FF and μ-Opioid Receptors as a Possible Molecular Basis for Anti-opioid Activity
Roumy, M., Lorenzo, C., Mazères, S., Bouchet, S. P., Zajac, J., & Mollereau, C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606946200 · Cited by 52
The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation
Rubio‐Araiz, A., Arévalo‐Martín, Á., Gómez, O., Navarro‐Galve, B., García‐Ovejero, D., Suetterlin, P., Sánchez-Heras, E., Molina‐Holgado, E., & Molina‐Holgado, F. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.03.010 · Cited by 50
Identification of intracellular peptides in rat adipose tissue: Insights into insulin resistance
Berti, D. A., Russo, L. C., Castro, L. M., Cruz, L., Gozzo, F. C., Heimann, J. C., Lima, F. B., de Oliveira, A. C., Andreotti, S., Prada, P. O., et al. (2012) · PROTEOMICS · doi:10.1002/pmic.201200051 · Cited by 49
Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia
Desroches, J., Bouchard, J., Gendron, L., & Beaulieu, P. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.12.030 · Cited by 49
Regulation of the AGS3·Gαi Signaling Complex by a Seven-transmembrane Span Receptor*
Öner, Ş. S., An, N., Vural, A., Breton, B., Bouvier, M., Blumer, J., & Lanier, S. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.138073 · Cited by 47
Opportunities for functional selectivity in GPCR antibodies
Webb, D. R., Handel, T. M., Kretz-Rommel, A., & Stevens, R. C. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.08.021 · Cited by 47

Authors: Rios, C., Gomes, I., & Devi, L. A.
Affiliations: Cornell University (US)
Icahn School of Medicine at Mount Sinai (US)
Corresponding author: Devi, Lakshmi A
ORCID: Gomes, Ivone
Devi, Lakshmi A
Venue: British Journal of Pharmacology
Publisher: Wiley
Published: 2006-06
Volume: 148
Issue: 4
Pages: 387-395
ISSN: 0007-1188 (ISSN-L)
1476-5381
DOI: 10.1038/sj.bjp.0706757
PMC: PMC1751792
OpenAlex: W1487872499
Cited by: 327
References: 42
Citations by year: 2026: 7 · 2025: 14 · 2024: 13 · 2023: 7 · 2022: 10 · 2021: 16 · 2020: 17 · 2019: 15 · 2018: 11 · 2017: 15 · 2016: 16 · 2015: 9 · 2014: 18 · 2013: 21 · 2012: 25
FWCI: 14.41
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 973 d)
Locations: British Journal of Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (DA08863)
National Institute on Drug Abuse (DA 08863, K05DA019521, R56DA008863, R37DA008863, DA19521, R01DA008863)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords: mu-opioid receptor, CB1 receptor, receptor-receptor interactions, opioid-cannabinoid interaction, neurite outgrowth, bioluminescence resonance energy transfer, CCR5 chemokine receptor, MAPK phosphorylation, Src phosphorylation, STAT3 phosphorylation, N2a cells
MeSH terms: Cells, Cultured, Humans, Phosphorylation, Signal Transduction, Guanosine 5'-O-(3-Thiotriphosphate), Neurites, Receptors, Opioid, mu, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Receptor, Cannabinoid, CB1, Extracellular Signal-Regulated MAP Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks